A Phase 1b, Multicenter, Open-label, Randomized Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis
Latest Information Update: 01 Aug 2025
At a glance
- Drugs AC-101-Accropeutics (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Accropeutics
Most Recent Events
- 01 Aug 2025 New trial record